
The FDA issued a complete response letter to the biologics license application for ivonescimab for use in combination with chemotherapy in EGFR-mutated NSCLC.
Cathy Eng, MD, FACP, FASCO, reviews the case of a 68-year-old diagnosed with metastatic NTRK fusion-positive colon cancer and shares treatments options.
Case: A 68-Year-Old Woman With Metastatic NTRK Fusion-Positive Colon Cancer
Initial presentation
Clinical workup






